Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

Delayed Quote. Delayed  - 08/31 10:00:00 pm
52.81 USD   -1.05%
08/03 OPHTHOTECH : reports 2Q loss
08/03 OPHTHOTECH : Reports Second Quarter 2016 Financial and Operating Res..
08/02 OPHTHOTECH : Announces Election of Ian F. Smith, Vertex Executive Vi..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Ophthotech : Announces Election of Ian F. Smith, Vertex Executive Vice President and Chief Financial Officer, to Its Board of Directors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/11/2016 | 08:05pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- Ophthotech Corporation (Nasdaq:OPHT) announced the election of Ian F. Smith, Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, to its Board of Directors, effective immediately. Mr. Smith has also been elected the Chair of the Ophthotech Audit Committee (see also Pharmaceutical Companies).

Mr. Smith has more than 15 years of experience in the biopharmaceutical industry; he currently serves as Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals, a global biotechnology company that discovers, develops and commercializes innovative medicines. Mr. Smith holds responsibility for core functions at Vertex, including Finance and Accounting, Investor Relations, Corporate and Business Development, Global Information Systems and Worldwide Operations, and he is a member of the Executive Team. Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm.

"We are excited to have attracted someone of Ian's stature to join our Board of Directors," stated David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board of Ophthotech. "Ian's outstanding and proven track record at Vertex and his financial, operations and commercial expertise will be beneficial to Ophthotech's future growth."

"Ophthotech is positioned to build on the strong momentum that it has established in the retina community," stated Mr. Ian F. Smith. "I am delighted to be a part of this passionate and committed team whose goal is to develop science-driven breakthrough therapies. I look forward to working closely with the other board members and the management team."

Keywords for this news article include: Vertex Pharmaceuticals, Investment and Finance, Ophthotech Corporation, Biotechnology Companies, Biopharmaceutical Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OPHTHOTECH CORP
08/11 OPHTHOTECH : Announces Election of Ian F. Smith, Vertex Executive Vice President..
08/11 OPHTHOTECH : Reports Second Quarter 2016 Financial and Operating Results
08/05 OPHTHOTECH : Management's Discussion and Analysis of Financial Condition and Res..
08/03 OPHTHOTECH : reports 2Q loss
08/03 OPHTHOTECH CORP. : Results of Operations and Financial Condition, Change in Dire..
08/03 OPHTHOTECH : Reports Second Quarter 2016 Financial and Operating Results
08/02 OPHTHOTECH : Announces Election of Ian F. Smith, Vertex Executive Vice President..
07/25 OPHTHOTECH CORPORATION : to Report Second Quarter 2016 Financial Results and Hos..
06/30 OPHTHOTECH : Completes Patient Recruitment in Phase 3 Trial of Fovista® Anti-PDG..
06/20 OPHTHOTECH : Completes Patient Recruitment in Phase 3 Trial of Fovista® Anti-PDG..
More news
Sector news : Bio Therapeutic Drugs
08/30DJFDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30DJNOVARTIS : FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/26 Healthcare ratings roundup - new coverage
08/17 BIOTECH FORUM DAILY DIGEST : Another Drug Approval For Aratana, Sorrento Makes S..
08/04 REGENERON'S Q2 : Opportunities And Challenges
08/03 Ophthotech's (OPHT) CEO David Guyer on Q2 2016 Results - Earnings Call Transc..
08/03 Ophthotech beats by $0.20, beats on revenue
Advertisement
Financials ($)
Sales 2016 67,8 M
EBIT 2016 -167 M
Net income 2016 -157 M
Finance 2016 263 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 24,1x
EV / Sales 2017 15,9x
Capitalization 1 900 M
More Financials
Chart OPHTHOTECH CORP
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Full-screen chart
Technical analysis trends OPHTHOTECH CORP
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 95,6 $
Spread / Average Target 79%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David R. Guyer Chairman & Chief Executive Officer
Samir Chandrakant Patel President & Vice Chairman
Glenn P. Sblendorio Treasurer, Chief Financial & Operating Officer
Harvey N. Masonson Senior Vice President-Clinical Development
Axel Bolte Independent Class II Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OPHTHOTECH CORP-32.04%1 900
AMGEN, INC.5.19%127 790
GILEAD SCIENCES, INC.-23.00%102 828
CELGENE CORPORATION-10.64%82 953
REGENERON PHARMACEUTIC..-27.20%41 614
VERTEX PHARMACEUTICALS..-23.87%23 737
More Results